Histogen to Present at the H.C. Wainwright Global Investment Conference
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, will have its Executive Chairman, Steven J. Mento, Ph.D., present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 a.m. Eastern Time. The presentation will focus on their innovative therapeutic developments for infectious and inflammatory diseases. It will be available on-demand and archived for 90 days on Histogen's investor page. Histogen is advancing treatments such as HST-003 for cartilage repair and emricasan for COVID-19 and other diseases.
- None.
- None.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Steven J. Mento, Ph.D., Histogen’s Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.
On-Demand Presentation Details
Date: Tuesday, May 24, 2022
Time: 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time)
Webcast Link: https://journey.ct.events/view/28269575-27c6-405a-8df1-1ae417047e5a
The on-demand presentation will be archived for 90 days and available through the Investors page on www.histogen.com.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing both potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function as well as a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases. Under our biologics technology platform, our product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. In addition, within our small molecule pipeline, our product candidates include emricasan, CTS-2090 and CTS-2096. Currently, emricasan is being developed jointly with our collaboration partner, Amerimmune, for the treatment of COVID-19, and we are evaluating the use of emricasan for other infectious diseases including the treatment of MRSA. We also have preclinical product candidates, CTS-2090 and CTS-2096, novel, potent, orally bioavailable, and highly selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
FAQ
What is the date and time of Histogen's presentation at the H.C. Wainwright Global Investment Conference?
How can I access Histogen's presentation after the event?
What are the key products being developed by Histogen?
What is the focus of Histogen's therapeutic developments?
Who is presenting for Histogen at the upcoming investment conference?
